Hypothesis being tested: Exercise-BDNF-Mitochondrial Resilience Hypothesis
Primary Objective: Determine whether physical exercise-induced BDNF elevation correlates with improved mitochondrial quality control markers and reduced neuroinflammation in Parkinson's Disease patients.
Study Design: Prospective cohort study with 12-month follow-up
- Age 45-75 years
- Diagnosis of idiopathic Parkinson's Disease (UK Brain Bank criteria)
- Hoehn & Yahr stage 1-3
- Stable dopaminergic medication for ≥4 weeks
- Able to participate in moderate exercise program
- Secondary parkinsonism
- Significant cardiovascular disease
- Orthopedic limitations preventing exercise
- Already engaged in structured exercise (>150 min/week)
- Cognitive impairment (MoCA <24)
- Total: 120 participants (60 exercise, 60 control)
- Power: 80% power to detect 20% difference in BDNF levels (α=0.05)
- Stratification: Equal BDNF Val66Met genotype distribution in both arms
- Type: Aerobic exercise (treadmill, cycling)
- Duration: 12 months
- Frequency: 3 sessions/week
- Intensity: 60-75% heart rate reserve
- Supervision: Bi-weekly in-person, home-based with weekly check-ins
- Intervention: Stretching and flexibility exercises (non-aerobic)
- Duration: 12 months
- Frequency: 2 sessions/week
- Intensity: Low intensity (RPE <10)
| Measure |
Timepoints |
Method |
| Serum BDNF |
Baseline, 3, 6, 12 months |
ELISA |
| Serum Parkin |
Baseline, 3, 6, 12 months |
ELISA |
| Serum PINK1 |
Baseline, 3, 6, 12 months |
ELISA |
| UPDRS Part III (Motor) |
Baseline, 3, 6, 12 months |
Clinical exam |
| Measure |
Timepoints |
Method |
| Neuroinflammation (IL-6, TNF-α) |
Baseline, 6, 12 months |
Multiplex ELISA |
| Mitochondrial DNA copy number |
Baseline, 6, 12 months |
qPCR |
| CSF BDNF (subset n=30) |
Baseline, 12 months |
ELISA |
| Autonomic function (SCOPA-AUT) |
Baseline, 12 months |
Questionnaire |
| Quality of life (PDQ-39) |
Baseline, 6, 12 months |
Questionnaire |
All participants genotyped for BDNF Val66Met polymorphism (rs6265):
- Val/Val: Expected normal BDNF trafficking
- Val/Met: Reduced activity-dependent BDNF secretion
- Met/Met: Significantly impaired BDNF release
The exercise-BDNF relationship may be attenuated in Met carriers due to impaired BDNF trafficking. This will be tested via interaction analysis.
- Mixed-effects linear regression (group × time interaction)
- Adjusted for: age, sex, disease duration, baseline UPDRS, medication dose
- Correlation: ΔBDNF vs ΔUPDRS, ΔBDNF vs mitochondrial markers
- Genotype stratification: Compare effect sizes by Val66Met genotype
- Mediation analysis: Does change in inflammatory markers mediate BDNF-motor association?
- n=60/group provides 80% power to detect:
- 25% increase in serum BDNF (Cohen's d=0.5)
- 15% reduction in UPDRS progression
- Exercise-related musculoskeletal injury
- Fatigue during exercise sessions
- Blood draw discomfort
- Supervised exercise program with gradual progression
- Exclusion of participants with cardiovascular contraindication
- Standard phlebotomy protocols
- Improved motor function
- Enhanced quality of life
- Potential disease-modifying effects (mechanistic)
| Item |
Cost |
| Personnel (2 research coordinators) |
20,000 |
| BDNF/Parkin/PINK1 ELISAs (720 assays) |
3,200 |
| Inflammatory marker panel (240 assays) |
4,400 |
| Genotyping (120 samples) |
,600 |
| Exercise equipment/supervision |
5,000 |
| Participant compensation |
6,000 |
| CSF collection (30 samples) |
,000 |
| Total |
51,200 |
- IRB approval required
- Informed consent for genotyping
- Genetic counseling available for participants
- Data safety monitoring board for adverse events
- Month 0-2: IRB approval, recruitment start
- Month 2-14: Enrollment (12 months)
- Month 14-26: Follow-up completion
- Month 26-30: Data analysis and manuscript preparation